利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.025 秒)

    Modified immunogenic pneumolysin compositions as vaccines
    1.
    发明授权
    Modified immunogenic pneumolysin compositions as vaccines 失效
    修饰的免疫原性肺炎溶蛋白组合物作为疫苗

    公开(公告)号：US06764686B2

    公开(公告)日：2004-07-20

    申请号：US09120044

    申请日：1998-07-21

    申请人： Conceicao Minetti ,  Francis Michon ,  Jeffrey K. Pullen ,  Mary Ellen Polvino-Bodnar ,  Shu-Mei Liang ,  Joseph Y. Tai

    发明人： Conceicao Minetti ,  Francis Michon ,  Jeffrey K. Pullen ,  Mary Ellen Polvino-Bodnar ,  Shu-Mei Liang ,  Joseph Y. Tai

    IPC分类号： A61K3902

    CPC分类号： C07K14/3156 ,  A61K39/092 ,  A61K2039/6037 ,  Y10S424/831 ,  Y10S530/825

    摘要： This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector. In addition, the invention also provides a method of using the non-toxic, modified pneumolysin toxoid in order to stimulate antibodies against Streptococcus pneumoniae in a treated individual which are then isolated and transferred to a second individual, thereby conferring protection against Streptococcus pneumoniae in the second individual.

    摘要翻译： 本发明涉及与天然气溶素相比，保留免疫原性的气溶菌素的修饰的气溶胶素多肽，但具有降低的或不可检测的溶血活性。 本发明还提供了一种产生具有这些所需特征性质的新型肺炎球菌变异体的方法。 本发明还提供可用作药物组合物的免疫原性组合物，包括其中无毒的改良的肺炎溶血杆菌刺激对肺炎链球菌的保护性免疫的疫苗。 疫苗可以是其中改性气溶胶与细菌多糖缀合或可以携带在减毒病毒载体上的组合物。 此外，本发明还提供了一种使用无毒的改良型肺炎杆菌素类毒素以刺激处理的个体中针对肺炎链球菌的抗体的方法，然后将其分离并转移到第二个体中，从而在肺炎链球菌中得到保护 第二个人。

    Group A streptococcal polysaccharide immunogenic compositions and methods
    6.
    发明授权
    Group A streptococcal polysaccharide immunogenic compositions and methods 失效
    A组链球菌多糖免疫原性组成及方法

    公开(公告)号：US07332173B2

    公开(公告)日：2008-02-19

    申请号：US11086214

    申请日：2005-03-21

    申请人： Milan S. Blake ,  John B. Zabriskie ,  Joseph Y. Tai ,  Francis Michon

    发明人： Milan S. Blake ,  John B. Zabriskie ,  Joseph Y. Tai ,  Francis Michon

    IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K38/00 ,  C07H1/00

    CPC分类号： A61K39/092 ,  A61K9/1271 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/6037 ,  Y10S424/831

    摘要： This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.

    摘要翻译： 本发明提供了一种新型的免疫原性组合物和疫苗，其制备方法以及针对由A组链球菌引起的感染和疾病的免疫方法。 组合物包括与蛋白质或脂质体共价连接以形成免疫原性缀合物的A组链球菌多糖。 本发明的免疫方法包括向个体施用免疫原性量的A组多糖。 A组多糖可以单独作为疫苗施用，与蛋白缀合或与脂质体缀合。 另外，A组多糖可以与佐剂结合。 本发明特别可用于为那些最具有承担A型链球菌感染和疾病风险的群体，即成年人，孕妇，特别是婴儿和儿童提供主动和被动免疫原性保护。

    Non-IgA Fc binding forms of the group B streptococcal &bgr; antigens
    7.
    发明授权
    Non-IgA Fc binding forms of the group B streptococcal &bgr; antigens 失效
    B组链球菌β抗原的非IgA Fc结合形式

    公开(公告)号：US06280738B1

    公开(公告)日：2001-08-28

    申请号：US08923992

    申请日：1997-09-05

    申请人： Joseph Y. Tai ,  Milan S Blake

    发明人： Joseph Y. Tai ,  Milan S Blake

    IPC分类号： A61K3909

    CPC分类号： C07K14/315 ,  A61K39/00 ,  Y10S424/831 ,  Y10S530/825

    摘要： A-X202X203X204X205X206X207X208X209X210X211X212X213-B, wherein A represents amino acid residues 38-201 of SEQ ID NO: 2, B represents a sequence starting from amino acid 214 of SEQ ID NO: 2 and terminating at an amino acid between residues 1131 and 1164, inclusive, of SEQ ID NO: 2, and X202 through X213 are each selected independently from Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, a bond, or a wild-type amino acid as found at a corresponding position of residues 202-213 of SEQ ID NO: 2, with the proviso that at least one of X202 through X213, inclusive, is other than the wild type amino acid found at the corresponding position of SEQ ID NO: 2. The LPXTG motif, as found in the native protein at amino acid residues corresponding to residues 1132-1136 of SEQ ID NO: 2, may be deleted in the sequence of the mutant C&bgr; protein. The mutant C&bgr; protein is conjugated to a streptococcal capsular polysacharide in a vaccine composition, also having an acceptable pharmaceutical carrier, for use in a method of including an immune response in an animal. Nucleic acid molecules encoding the mutant protein, vectors containing these molecules, and host cells transformed therewith are also disclosed.

    摘要翻译： A-X202X203X204X205X206X207X208X209X210X211X212X213-B，其中A表示SEQ ID NO：2的氨基酸残基38-201，B表示从SEQ ID NO：2的氨基酸214开始并终止于残基1131和1164之间的氨基酸 ，SEQ ID NO：2，X202〜X213各自独立地选自Ala，Val，Leu，Ile，Pro，Met，Phe，Trp，键或野生型氨基酸， SEQ ID NO：2的残基202-213，条件是X202至X213中的至少一个不包括在SEQ ID NO：2的相应位置发现的野生型氨基酸。LPXTG基序作为 在对应于SEQ ID NO：2的残基1132-1136的氨基酸残基处的天然蛋白质中发现的，可以在突变型Cbeta蛋白质的序列中缺失。 在具有可接受的药物载体的疫苗组合物中，突变体Cbeta蛋白质与链球菌荚膜多糖偶联，用于在动物中包含免疫应答的方法。 还公开了编码突变蛋白的核酸分子，含有这些分子的载体和用其转化的宿主细胞。

    Vaccines against group C Neisseria meningitidis
    8.
    发明授权
    Vaccines against group C Neisseria meningitidis 失效
    疫苗针对C组脑膜炎奈瑟氏球菌

    公开(公告)号：US5425946A

    公开(公告)日：1995-06-20

    申请号：US938367

    申请日：1992-08-31

    申请人： Joseph Y. Tai ,  Lucjan J. J. Hronowski ,  Sharon Mates

    发明人： Joseph Y. Tai ,  Lucjan J. J. Hronowski ,  Sharon Mates

    IPC分类号： A61K39/095 ,  G01N33/68 ,  C07K1/10

    CPC分类号： A61K39/095 ,  G01N33/6854 ,  A61K2039/6037 ,  Y10S530/807

    摘要： An immunogenic conjugate comprising a modified group C meningococcal polysaccharide (GCMP) coupled to a carrier molecule. The GCMP is modified by O-deacetylation to a varying extent. This modified GCMP conjugate stimulates a strong immunogenic response. The antiserum, produced by immunization with this conjugate, is cross-reactive with the native polysaccharide. In addition, these antisera elicit a class of antibodies that have patent bactericidal activity.

    摘要翻译： 包含与载体分子偶联的修饰的C组脑膜炎球菌多糖（GCMP）的免疫原性缀合物。 通过O-去乙酰化可以改变GCMP的程度。 该修饰的GCMP缀合物刺激强的免疫原性反应。 通过用该缀合物免疫产生的抗血清与天然多糖交叉反应。 此外，这些抗血清引起一类具有专利杀菌活性的抗体。